Safety and Efficacy of FOLFIRI-3 (Split-Dose Irinotecan) for Unresectable Colorectal Cancer: A Stratified Analysis Based on UGT1A1 Gene Polymorphisms
Cancers · 26.04.2026 · 18 (9) · 1377
DOI: 10.3390/cancers18091377 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 26.04.2026. Verfasst von Gaku Ohira und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Frontier Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8677, Japan. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
UGT1A1 gene polymorphisms are established risk factors for irinotecan (CPT-11)-induced toxicity. The FOLFIRI-3 regimen, incorporating split-dose CPT-11 administration on Days 1 and 3, was developed to improve safety and efficacy. This study evaluated the clinical outcomes of FOLFIRI-3 stratified by UGT1A1 genotype.
Methods
We retrospectively analyzed 147 patients with unresectable metastatic colorectal cancer (mCRC) treated with first-line FOLFIRI-3 between 2005 and 2020 who underwent UGT1A1 genotyping for *6 and *28 variants. During this period, FOLFIRI-3 was adopted as the standard first-line regimen for all eligible patients at our institution to standardize toxicity management. Patients were classified into three groups: Wild-type (negative for both variants; n = 82), Single-heterozygous (SH; n = 56), and Homo/Compound heterozygous (HCH; n = 8) group.
Results
The HCH group maintained a relative dose intensity (RDI) of 57.7% with manageable toxicity. While time to treatment discontinuation (TTD) did not differ significantly among groups, overall survival (OS) was significantly longer in the SH group compared to the Wild-type group (Median Survival Time: 30.4 vs. 21.7 months, p = 0.0058).
Conclusions
For high-risk HCH patients, our findings regarding the tolerability of FOLFIRI-3 are strictly preliminary due to the small sample size and require further validation in larger, multi-institutional cohorts. Despite this limitation, this regimen serves as a valuable alternative for high-risk patients and provides superior survival benefits for single heterozygotes, likely due to optimized pharmacokinetics.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Frontier Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8677, Japan.
- Department of Surgery, Saisei Hospital, 800-1 Kashiwai, Hanamigawa-ku, Chiba 262-8506, Japan.
- Department of Laboratory Medicine, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba 260-8677, Japan.
- Department of Applied Genomics, Kazusa DNA Research Institute, 2-6-7 Kazusa-kamatari, Kisarazu, Chiba 292-0818, Japan.
- Department of Surgery, Teikyo University Chiba Medical Center, 3426-3 Anesaki, Ichihara, Chiba 299-0111, Japan.
ORCID-Profile: Toru Tochigi, Koichiro Okada, Atsushi Hirata, Michihiro Maruyama, Takayuki Ishige, Kazuyuki Matsushita, Kiyohiko Shuto
Zitieren
APA
Ohira, G., Miyauchi, H., Tochigi, T., Maruyama, T., Okada, K., Hirata, A., Ikeda, Y., Hayano, K., Maruyama, M., Ishige, T., Matsushita, K., & Shuto, K. (2026). Safety and Efficacy of FOLFIRI-3 (Split-Dose Irinotecan) for Unresectable Colorectal Cancer: A Stratified Analysis Based on UGT1A1 Gene Polymorphisms. Cancers, 18(9), 1377. https://doi.org/10.3390/cancers18091377
Vancouver
Ohira G, Miyauchi H, Tochigi T, Maruyama T, Okada K, Hirata A, et al. Safety and Efficacy of FOLFIRI-3 (Split-Dose Irinotecan) for Unresectable Colorectal Cancer: A Stratified Analysis Based on UGT1A1 Gene Polymorphisms. Cancers. 2026;18(9):1377. doi:10.3390/cancers18091377
BibTeX
@article{Ohira2026,
author = {Ohira, Gaku and Miyauchi, Hideaki and Tochigi, Toru and Maruyama, Tetsuro and Okada, Koichiro and Hirata, Atsushi and Ikeda, Yuko and Hayano, Koichi and Maruyama, Michihiro and Ishige, Takayuki and Matsushita, Kazuyuki and Shuto, Kiyohiko},
title = {Safety and Efficacy of FOLFIRI-3 (Split-Dose Irinotecan) for Unresectable Colorectal Cancer: A Stratified Analysis Based on UGT1A1 Gene Polymorphisms},
journal = {Cancers},
year = {2026},
volume = {18},
number = {9},
pages = {1377},
doi = {10.3390/cancers18091377}
}
EUVIMED